Advances in Combination Therapy for Gastric Cancer: Integrating Targeted Agents and Immunotherapy
Advances in Clinical Pharmacology and Therapeutics · 2024
DOI: 10.63623/9k14tf70 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Clinical Pharmacology and Therapeutics, 2024. Verfasst von Jun Ren. Die Arbeit wurde bisher 26-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Despite the recent advancement in the diagnostic and therapeutic approaches, gastric cancer continues to be one of the most cardinal causes of the cancer death globally. Trends of the recent years in composite treatments that integrate biomarkers with immunotherapy along with well-tailored and individualized aggregate remedies introduce perspectives for the optimization of the outcomes.
Objective
The present review intends to qualify to give as much and more than a very comprehensive update on the latest developments of the pool of targeted agents and immunotherapy for gastric cancer, focusing on the mechanisms, medical trial effects, and future directions.
Methods
The papers for the review were identified through a comprehensive search of both PubMed as well as other databases represented in the actual journals. The filter used for search was the actual last 10 years. As for the criteria for inclusion on the studies it was only the relevance of the material, and their experience on combination remedies in gastric cancers.
Results
The combination of the former therapies, namely the human epidermal growth factor receptor 2 (HER2 inhibitors), Vascular Endothelial Growth Factor (VEGF) inhibitors, and mesenchymal-epithelial transition (MET) inhibitors has demonstrated better efficiency in various clinical trials not to mention having the right immune checkpoint inhibitors. The most important findings of current literature suggest that there is presumably cooperative interaction of all of these components, which results in more accurate anti-tumor reactions and better survival rates.
Conclusion
The inclusion of combination therapy should be highly included into recommended treatment plans for gastric cancer, especially for patients with certain molecular profiles. The evidence suggests that the combination of targeted treatment programs with immunotherapy provides significant advantages compared to typical monotherapy approaches, including increased effectiveness and improved overall survival rates.
Zitieren
APA
Ren, J. (2024). Advances in Combination Therapy for Gastric Cancer: Integrating Targeted Agents and Immunotherapy. Advances in Clinical Pharmacology and Therapeutics. https://doi.org/10.63623/9k14tf70
Vancouver
Ren J. Advances in Combination Therapy for Gastric Cancer: Integrating Targeted Agents and Immunotherapy. Advances in Clinical Pharmacology and Therapeutics. 2024. doi:10.63623/9k14tf70
BibTeX
@article{Ren2024,
author = {Ren, Jun},
title = {Advances in Combination Therapy for Gastric Cancer: Integrating Targeted Agents and Immunotherapy},
journal = {Advances in Clinical Pharmacology and Therapeutics},
year = {2024},
doi = {10.63623/9k14tf70}
}
EUVIMED